Evidence map›Paper›PMID 18422756›Full record

ArticleCancer science2008

Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate.

Xun Li, Zhenyu Jia, Yongquan Shen, Hitoshi Ichikawa, Jonathan Jarvik, Robert G Nagele, Gary S Goldberg

Open access · bronzeAbstract read
In one paragraph

Article in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Xun LiMolecular Biology Department, University of Medicine and Dentistry of New Jersey, Stratford, NJ 08084, USA.
Zhenyu Jia
Yongquan Shen
Hitoshi Ichikawa
Jonathan Jarvik
Robert G Nagele
Gary S Goldberg
Rutgers, The State University of New Jersey · USCarnegie Mellon University · USNational Cancer Research Institute · GBStratford University · US

Funding

TECHNOLOGIES FOR COMPREHENSIVE FUNCTIONAL PROTEOMICSR33CA083219 · NCI · CARNEGIE-MELLON UNIVERSITY · PI JARVIK, JONATHAN W · 2000 to 2002
$2.4M
The Src Kinase, cell communication &growth controlR01CA088805 · NCI · UNIV OF MED/DENT NJ-SCH OSTEOPATHIC MED · PI GOLDBERG, GARY S · 2002 to 2006
$1.1M
NCI NIH HHS CA88805NCI NIH HHS R01 CA088805
6 · The paper itself

Abstract

The Src tyrosine kinase associates with the focal adhesion adaptor protein Cas (Crk-associated substrate) to suppress the expression of potential tumor suppressor genes. For example, Src utilizes Cas to suppress the expression of the LIM-only protein Fhl1 (four and a half LIM domains 1), in order to promote non-anchored tumor-cell growth and migration. Here, we report that the promoter region of the Fhl1 gene was methylated more in Src-transformed cells than non-transformed cells. In addition, global expression analysis indicates that Fhl1 induced expression of serum deprivation response factor (Sdpr) in Src-transformed cells. Moreover, Fhl1 and Sdpr was expressed in approximately 87% and 40% of samples obtained from non-transformed breast, 100% of samples obtained from non-transformed kidney, and over 60% of samples obtained from non-transformed prostate. In contrast, Fhl1 and Sdpr was detected in approximately 40% and 7% of matched samples from mammary carcinoma, less than 11% of matched samples from kidney carcinoma, and in less than 22% of matched samples from prostate carcinoma. These data indicate that Fhl1 and Sdpr expression was significantly reduced in tumors of the breast (P < 0.02 and P < 0.001), kidney (P < 0.01), and prostate (P < 0.05). In addition, although Src can activate mitogen-activated protein kinase (MAPK) to promote tumor-cell growth, our data indicate that Src did not rely on MAPK activity to suppress the expression of Fhl1 and Sdpr in transformed cells. Thus, Src induced methylation of the promoter region of the Fhl1 gene; Src suppressed Fhl1 and Sdpr expression independent of mitogen-activated protein kinase (MAPK) activity; Fhl1 induced the expression of Sdpr in Src-transformed cells; and Fhl1 and Sdpr expression was suppressed in tumors of the breast, kidney, and prostate.

Indexed as

AnimalsBreast NeoplasmsCarrier ProteinsCell Transformation, NeoplasticCrk-Associated Substrate ProteinDisease ProgressionDNA MethylationFemaleHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsKidney NeoplasmsLIM Domain ProteinsMaleMiceMuscle ProteinsCarrier ProteinsCAVIN2 protein, humanCrk-Associated Substrate ProteinFHL1 protein, humanIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMuscle ProteinsPhosphate-Binding Proteinssrc-Family Kinases

Identifiers

PMID18422756
PMCPMC11158056
OpenAlexW2003073557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.